Adolescent GLP-1 Receptor Agonists
Adolescent obesity affects 19.7% of youth in the U.S., and Glucagon-like Peptide Receptor Agonists are now widely used for this indication. However, the developmental and long-term consequences when used during this critical period of growth are unknown.
